夏伟雄 - 中山大学 - 肿瘤防治中心

个人简介

学习及工作经历 2009.9-2014.6　　中山大学肿瘤防治中心　肿瘤学专业　获博士学位 2014.7-2016.12　中山大学肿瘤防治中心　鼻咽科　　　住院医师 2017.1-2018.12　中山大学肿瘤防治中心　鼻咽科　　　主治医师 2019.1-至今　　　中山大学肿瘤防治中心　鼻咽科　　　副主任医师 2018.8-2019.2　　廉江市人民医院　　　　肿瘤血液科　业务主任（挂职） 2018.8-2019.2　　廉江市人民医院　　　　耳鼻喉科　　技术顾问（挂职） 2012.12-2013.12　美国佛罗里达州立大学　访问学者

研究领域

①鼻咽癌个体化治疗；②转移鼻咽癌的治疗；③鼻咽癌预后。

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1、A prognostic model predicts the risk of distant metastasis and death for patients with nasopharyngeal carcinoma based on pre-treatment serum C-reactive protein and N-classification. Xia W X, Zhang H B, Shi J L, et al. European journal of cancer, 2013, 49(9): 2152-2160. Article 2、A novel statistical prognostic score model that includes serum CXCL5 levels and clinical classification predicts risk of disease progression and survival of nasopharyngeal carcinoma patients[J]. Zhang H, Xia W(共同第一), Lu X, et al. PloS one, 2013, 8(2): e57830. article. 3、A novel statistical prognostic score model that includes serum CXCL5 levels and clinical classification predicts risk of disease progression and survival of nasopharyngeal carcinoma patients[J]. Zhang H, Xia W(共同第一), Lu X, et al. PloS one, 2013, 8(2): e57830. article. 4、A model to predict the risk of lethal nasopharyngeal necrosis after re-irradiation with intensity-modulated radiotherapy in nasopharyngeal carcinoma patients[J]. Yu Y H, Xia W X┼, Shi J L, et al. Chinese Journal of Cancer, 2016, 35(1): 59. article. 5、A prognostic model predicts the risk of distant metastasis and death for patients with nasopharyngeal carcinoma based on pre-treatment interleukin 6 and clinical stage. Ke L, Xiang Y, Xia W(共同第一), Yang J, Yu Y, Ye Y, et al. Clinical Immunology. 2016;164:45-51. 6、Combining cetuximab with chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: A propensity score analysis. Xia W X, Liang H, Lv X, et al. Oral Oncology, 2017, 67: 167-174. 7、A phase II trial of induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma. Ke L R, Xia W X(共同第一), Qiu W Z, et al. Oral oncology, 2017, 70: 7-13 8、Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial. Ke L R, Xia W X(共同第一), Qiu W Z, et al. BMC cancer, 2017, 17(1): 134. 9、Survival impact of waiting time for radical radiotherapy in nasopharyngeal carcinoma: A large institution-based cohort study from an endemic area. Liang H, Xiang YQ, Lv X …Xia WX*. European Journal of Cancer, 2017, 73: 48-60. 10、Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis. Liu G Y, Lv X, Wu Y S…Xia WX*. 11、 Disrupting SOD1 activity inhibits cell growth and enhances lipid accumulation in nasopharyngeal carcinoma. Li, S., Fu, L., Tian, T., Deng, L., Li, H., Xia, W.(共同通讯), Gong, Q. 12、The plasma Epstein-Barr virus DNA level guides precision treatment for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a large population-based cohort study from an endemic area. Liang H, Lv X, Wang L…Xia WX*.Therapeutic advances in medical oncology, 2018, 10: 1758835918782331. 13、The prognostic significance of carcinoma-associated fibroblasts and tumor-associated macrophages in nasopharyngeal carcinoma. Yu Y, Ke L, Lv X…Xia WX(共同通讯), Xiang YQ. Cancer management and research, 2018, 10: 1935. 14、Concurrent Chemoradiotherapy versus Intensity-modulated Radiotherapy Alone for Elderly Nasopharyngeal Carcinoma Patients with Pre-treatment Epstein-Barr Virus DNA: A Cohort Study in an Endemic Area with Long-term Follow-up. Yang Q, Zhao TT, Qiang MY…Xia WX*. Journal of Cancer, 2018, 9(17): 3023 15、Platinum-based concurrent chemotherapy remains the optimal regimen for nasopharyngeal carcinoma: a large institutional-based cohort study from an endemic area. Yu Y, Liang H, Lv X…Xia WX*.Journal of cancer research and clinical oncology, 2018, 144(11): 2231-2243.